Dr. Meng on MRI-US Fusion Targeted Biopsy for High-Grade Prostate Cancer

Video

In Partnership With:

Xiaosong Meng, MD, PhD, NYU Langone Medical Center, discusses MRI-US fusion targeted biopsies and how they can be used to identify high-grade prostate cancers.

Xiaosong Meng, MD, PhD, NYU Langone Medical Center, discusses MRI-US fusion targeted biopsies and how they can be used to identify high-grade prostate cancers.

Following results of an increase prostate-specific antigen (PSA) score, patients undergo a systematic biopsy, known as a traditional method of diagnosing prostate cancer, Meng explains. This method is a random sampling; therefore, imaging is being used to improve the detection of localization of prostate cancer. For example, a multi-parametric MRI is a combination of anatomic and functional sequences that allow for increased localization.

From this imaging technique, each abnormality is given a suspicion score from 1 to 5, with 5 being the most likely to be cancerous, Meng explains. Practitioners then perform a MRI-US fusion targeted biopsy, which allows them to better target lesions. A recent study showed that patients with an increasing MRI suspicion score does correlate with identifying high-grade prostate cancer.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD